Antiphospholipid syndrome and cancer
Antiphospholipid antibodies syndrome (APS) is an acquired prothrombotic status, that is due to the occurrence of a certain type of autoantibodies directed against negatively charged phospholipid structures – hence the name. Neoplasia is also characterized by a systemic procoagulant status, through v...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2021-03-01
|
| Series: | Romanian Journal of Rheumatology |
| Subjects: | |
| Online Access: | https://rjr.com.ro/articles/2021.1/RJR_2021_1_Art-02.pdf |
| _version_ | 1819034144765640704 |
|---|---|
| author | Razvan Adrian Ionescu |
| author_facet | Razvan Adrian Ionescu |
| author_sort | Razvan Adrian Ionescu |
| collection | DOAJ |
| description | Antiphospholipid antibodies syndrome (APS) is an acquired prothrombotic status, that is due to the occurrence of a certain type of autoantibodies directed against negatively charged phospholipid structures – hence the name. Neoplasia is also characterized by a systemic procoagulant status, through various mechanisms. Obviously, both conditions may occur in the same patient, raising the question of a possible causal relation. Regardless of
the potential liaison between the two events, clinicians caring for neoplastic patients as well as for APS patients, should be aware of the presence of both conditions in the same patient, as this has important therapeutic consequences. |
| first_indexed | 2024-12-21T07:29:04Z |
| format | Article |
| id | doaj.art-9d99493d29f24866baac5b44b42c24b0 |
| institution | Directory Open Access Journal |
| issn | 1843-0791 2069-6086 |
| language | English |
| last_indexed | 2024-12-21T07:29:04Z |
| publishDate | 2021-03-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Rheumatology |
| spelling | doaj.art-9d99493d29f24866baac5b44b42c24b02022-12-21T19:11:37ZengAmaltea Medical Publishing HouseRomanian Journal of Rheumatology1843-07912069-60862021-03-01301111410.37897/RJR.2021.1.2Antiphospholipid syndrome and cancerRazvan Adrian Ionescu05th Department, Internal Medicine, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; 3rd Clinic, Internal Medicine, Colentina Clinical Hospital, Bucharest, RomaniaAntiphospholipid antibodies syndrome (APS) is an acquired prothrombotic status, that is due to the occurrence of a certain type of autoantibodies directed against negatively charged phospholipid structures – hence the name. Neoplasia is also characterized by a systemic procoagulant status, through various mechanisms. Obviously, both conditions may occur in the same patient, raising the question of a possible causal relation. Regardless of the potential liaison between the two events, clinicians caring for neoplastic patients as well as for APS patients, should be aware of the presence of both conditions in the same patient, as this has important therapeutic consequences.https://rjr.com.ro/articles/2021.1/RJR_2021_1_Art-02.pdfantiphospholipid syndromeantiphospholipid antibodiescancer |
| spellingShingle | Razvan Adrian Ionescu Antiphospholipid syndrome and cancer Romanian Journal of Rheumatology antiphospholipid syndrome antiphospholipid antibodies cancer |
| title | Antiphospholipid syndrome and cancer |
| title_full | Antiphospholipid syndrome and cancer |
| title_fullStr | Antiphospholipid syndrome and cancer |
| title_full_unstemmed | Antiphospholipid syndrome and cancer |
| title_short | Antiphospholipid syndrome and cancer |
| title_sort | antiphospholipid syndrome and cancer |
| topic | antiphospholipid syndrome antiphospholipid antibodies cancer |
| url | https://rjr.com.ro/articles/2021.1/RJR_2021_1_Art-02.pdf |
| work_keys_str_mv | AT razvanadrianionescu antiphospholipidsyndromeandcancer |